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A clinically mild form of sickle cell disease, characterized by 
high hemoglobin F levels (in the range of 15-25%) is common in 
Kuwait. Studies have shown that selective regulation after gene 
expression of the two copies of the y globin gene is one factor 
involved in controlling HbF persistence into adult life. The Ay and Gy 
globin genes of the (3 globin gene cluster are identical except at 
position 136 where either alanine (Ay) or glycine (Gy) is present. At 
birth, when HbF levels are relatively high, the Gy: Ay ratio is 7:3. As 
development proceeds, HbF levels decline sharply and the ratio 
changes to the adult value of 2:3. 
In this study, we analyzed blood samples from 7 pedigree 
families (totalling 25 samples) and 6 unrelated individuals with 
various sickle cell syndromes. Hemoglobin lysates and globin 
preparations were electrophoresed on 12.5% polyacrylamide gels 
with 6M urea, 2% Triton X-100 in 5% acetic acid, to separate the [3,a, 
Ay and Gy globin chains for analysis. HbF levels were determined 
using alkali depaturation. 
Our results revealed an equal proportion of Gy and Ay globin 
chains and high HbF levels (ranging from 10.4%-60.7% in sickle cell 
patients), suggestive of a type of heterocellular persistence of fetal 
hemoglobin. However, neither Saudi Arabian or Kuwaiti sickle cell 
patients exhibit classical deletion or nondeletion HPFH, since 
parents of affected individuals did not have high HbF. 
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I. GENETIC BASIS OF SICKLE CELL DISEASE 
Sickle hemoglobin ,HbS, is formed due to a simple point 
mutation in DNA in which thymine replaces an adenine residue in the 
sixth codon of exon 1 of the (3 globin gene. During subsequent 
protein synthesis that leads to the production of the (3-globin chain, 
valine substitutes for glutamic acid in the sixth position. 
Sickle cell anemia is a genetically inherited disease. Parents 
of affected individuals have either the heterozygous carrier 
condition known as sickle cell trait ,Hb AS, or are homozygous for 
sickle hemoglobin ,Hb SS. 
The term sickle cell disease covers a spectrum of disorders 
ranging from the almost benign carrier state of sickle trait, to 
disorders of intermediate severity (Sickle (3°-thalassemia, Sickle 
(3+-thalassemia, Sickle a°-thalassemia, Sickle a+-thalassemia) to 
the most severe form - the SS phenotype. Also included in the 
category of sickle cell syndromes are Hb SC disease, Hb SD disease 
and Hb SO Arab disease. (16) 
The increased clinical morbidity associated with these doubly 
heterozygous conditions compared to that seen with sickle cell trait 
is due to several factors. These factors include: 
1) The presence of a second hemoglobin gene or mutant genes that 
leads to absent or reduced amounts of normal hemoglobin A. 
(i.e. Sickle (3-thalassemia.) 
2) The presence of a mutant [3-chain that causes cellular 
dehydration and therefore increased intracellular hemoglobin S 
concentration, (i.e. Hb SC disease) 
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3) The presence of a hemoglobin that participates in 
polymerization to a greater degree than hemoglobin A does. 
(i.e. Hb >SS and SO arab diseases) (33) 
Epidemiological studies have shown that sickle cell syndromes 
have their highest prevalence in Black Africans and their 
descendents. However, the sickle gene has been found in Iran, Italy, 
Greece, Israel, India, Saudi Arabia and Kuwait. 
The association between the sickle mutation and at least three 
separate restriction enzyme polymorphism haplotypes suggests that 
its distribution throughout the world is the result of multiple 
mutational events and dissemination via various trade routes. (13) 
Geographically, the [3s gene is most concentrated in two areas 
of West Central Africa. One of these areas encompasses Nigeria and 
Ghana and the other Gabon and Zaire. It has been estimated that in 
these areas, as many as 25% of all newborns are AS heterozygotes. 
In African-Americans, the frequency of AS heterozygotes ranges 
from 7-10%. (16) 
The sickle hemoglobin gene is also quite common in East 
Central India and in the north eastern region of Saudi Arabia (the 
Shia Oasis). Historical evidence suggests that the high prevalence 
of the (3s gene in Saudi Arabia and India may have arisen from 
migrations out of East Africa. African slaves were transported from 
East Africa to the Persian Gulf from 200-1500 A.D. There was also 
active slave trading to India from East Africa up until the 19th 
century. The frequency of the [3s gene in North, South, and Central 
America as well as the Caribbean is also linked to the slave trade 
that originated in West Africa. (16) 
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Evidence for several independent origins for the sickle cell 
mutation enhances epistasis (i.e. the effects of linked and unlinked 
genes on sickle gene expression) as demonstrated by hematological 
differences between SS individuals from Benin and Senegal that have 
different polymorphism hap!otypes.(33) A map of the various ps 
polymorphic sites has been deduced with the use of restriction 
enzymes. These enzymes recognize short, specific sequences of DNA 
for cleavage. The presence or absence of a particular site is denoted 
by a + or - sign. These haplotype maps allow investigators to refer 
to various polymorphisms via a simplified schematic 
representation. Figure 1 demonstrates these various haplotypes. A 
previous study describes the haplotype (—++-+) in chromosomes 
from individuals from Nigeria, the southwest of the Arabian 
peninsula, West Africa, Jamaica and the U.S. A different haplotype 
(++-++++-) not found in Africa, is seen in the eastern oases of Saudi 
Arabia and the west and east coast of India. The geographic 
distribution of the Asian (3s haplotype corresponds to the 
distribution of a clinically milder form of homozygous sickle cell 
disease associated with high levels of fetal hemoglobin (HbF). (51) 
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II. THE PATHOPHYSIOLOGY OF SICKLE CELL DISEASE 
Under deoxygenated conditions such as those found in parts of 
the venous and capillary circulation, sickle hemoglobin undergoes 
polymer formation. NMR studies reveal that deoxygenated sickle 
cells become rigid even before they sickle and suggests that the 
accumulation of polymer leads to decreased cellular deformability 
and vaso-occlusion at precapillary sphincter levels. (33) 
As the sickle red blood cells course through the circulatory 
system they undergo cellular dehydration and acquire a high MCHC 
and cell density. As sickle cells undergo deoxygenation they 
experience potassium leakage, and calcium influx and achieve a 
"sickle" shape. As this occurs, intracellular water is also lost in an 
attempt to reestablish osmotic balance. (33) 
Several hypotheses have been formulated to explain the volume 
loss seen in sickle cells. They are as follows: 
1) The phase transition of Hb S induces a direct volume 
difference between cells. 
2) Hemoglobin gelation leads to decreased osmotic pressures. 
3) Membrane stretching during sickling may lead to a disturbance 
in the cation homeostatic state. 
Since HbS occupies the same volume in the gel and sol phases and 
the production of polymer and its effects on osmotic pressure do not 
sufficiently account for the volume loss seen, the later hypothesis 
involving membrane stretching appears to be the most scientifically 
sound of the three theories. (33) 
In 1940, Drs. Ham and Castle proposed that a "vicious cycle of 
erythrostasis" explained the clinical nature of sickle cell disease. 
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They hypothesized that the dehydration and polymerization of 
hemoglobin S in sickle cells results in rheologic abnormalities that 
are thought to account for the vaso-occlusion, painful crises, tissue 
infarction and chronic hemolytic anemia seen in sickle cell patients. 
The rheologic impairment of sickle cells is due to: 
1) Poor deformability of sickle cells. 
2) Concentration of sickle cells in blood. 
3) The increased adhesiveness of sickled cells to capillary 
endothelial cells. 
4) The effects of sickled cells on whole blood viscosity. 
Although the theory of the "vicious cycle of erythrostasis" 
remains to be proven scientifically, it has generally been accepted 
that vaso-occlusion is the main culprit responsible for the clinical 
manifestations of sickle cell disease.(33) 

III. CLINICAL MANIFESTATIONS OF SICKLE CELL DISEASE 
Individuals with sickle cell anemia are usually well at birth 
and become symptomatic between six months and twelve months of 
age. By ten to twelve weeks of age, red blood cell sickling, 
hemolytic anemia and increased levels of reticulocytosis becomes 
apparent in sickle cell patients. Infants with SS disease may appear 
clinically well since the major hemoglobin present at birth and for 
several months after birth is HbF. (33) In children, the clinical 
effects of sickle cell disease are usually acute and infectious in 
nature. However, adults with sickle cell disease tend to 
demonstrate chronic organ related damage from uncontrolled 
sickling. (78) 
Studies designed by Scott et al., Ferguson et al., Porter et al., 
and others examined the clinical manifestations of sickle cell 
disease during the first year of life. Generalized dactylitis (hand- 
foot syndrome), infectious diseases and splenic sequestration crises 
were noted as major areas of clinical difficulty. (78) 
Splenic sequestration crisis can be life threatening. During 
these episodes, children with progressive splenomegaly become 
severely anemic in the presence of actual or imminent shock. It has 
been theorized that the splenic sequestration crisis involves an 
accumulation of blood in the spleen. (16) 
Pearson and O'Brien have found that sickle cell patients 
demonstrate changes in the reticuloendothelial function of the 
spleen during the first year of life. Children with sickle cell anemia 
often have splenomegaly by five to six months of age. As the spleen 
size increases, there is decreased phagocytic activity of the 

reticuloendothelial cells in the spleen, demonstrated by isotopic 
techniques which reveal elevated numbers of "pocked" RBCs in the 
bloodstream. This leads one to conclude that children with sickle 
cell disease experience a type of functional asplenia as they mature. 
In African and American sickle cell patients it is typical to find that 
splenic infarction has occurred in older children (> 7 years of age) 
and adults. (78) 
Children with sickle cell anemia have an increased 
susceptibility to contracting infectious diseases. Immunologic 
defects in the alternate complement pathway of sickle cell anemia 
patients leads to slow chemotaxis and inefficient phagocytosis by 
polymorphonuclear leukocytes. These factors as well as the 
functional asplenia exhibited by patients with sickle cell anemia 
most likely account for the increased prevalence of infectious 
processes in this group. (78) Incidents of sudden death in children 
with sickle cell anemia are often due to overwhelming 
pneumococcal septicemia. (78) 
The sickle cell crisis is the hallmark of sickle cell disease and 
is characterized by excruciating pain in the back, extremities, chest 
and/or abdomen. Events that provoke painful crises still remain 
unclear; however these crises are often preceded by infection, 
dehydration, physical or emotional stress. (94) 
The hemolytic anemia caused by Hb SS is usually moderate and 
often is overestimated due to plasma volume expansion. The anemia 
in and of itself is not a significant determinant of disease severity. 
The subsequent marrow expansion, hyperplasia of erythroid marrow 
and increased turnover of bile pigments (and its clinical 

consequences of cholelithiasis) are problems encountered in all 
types of hemolytic anemias. With proper medical management these 
conditions can be compatible with a fairly normal, comfortable, long 
life. The vaso-occlusive effects of sickle cell anemia and 
subsequent damage to vital organs plays the major role in 
determining the degree of morbidity and mortality associated with 
the disease. (94) 
The acute chest syndrome which presents with intense onset 
of fever, leukocytosis, pain on inspiration and expiration, dyspnea 
and cough is a common cause of hospitalization in sickle cell 
patients. Methods to accurately distinguish between micro- 
infarctive events and infectious processes in the pulmonary system 
have yet to be developed. (16) 
Patients with sickle cell disease may also experience 
neurological deficits and seizures as a result of a cerebrovascular 
accident. Children with sickle cell disease also have delayed growth 
and development. Adults with sickle cell anemia commonly exhibit 
chronic organ damage that is most pronounced in the spleen, heart, 
lungs, kidneys, eyes and bones. 
The major renal complications of sickle cell disease are 
uremia, hyposthenuria, nephrotic syndrome, and hematuria. (77) 
Microinfarction of the renal papillae can cause a loss of the ability 
to concentrate and dilute urine. This isosthenuria in turn leads to 
zinc deficiency and wasting. (10) Such organ system failure can in 
turn become life threatening. 
The lifetime prognosis of patients of sickle cell disease in the 
U.S. is not known. In 1970, Scott calculated a median expected 
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survival of 20 years of age using data from the U.S. Bureau of Vital 
Statistics. Today, therapeutic interventions aimed at preventing 
dehydration, maintaining fluid balance and halting the spread of 
infections has not made it unusual for sickle cell patients in 
industrialized nations to survive into and beyond the third and fourth 
decades. (16) 

IV. CLINICAL HETEROGENEITY IN THE SICKLE CELL SYNDROMES 
One of the most striking features about sickle cell anemia is 
the broad spectrum of clinical severity seen in affected patients. 
For example, some patients are incapacitated by recurrent episodes 
of painful crises and ensuing organ damage while other patients 
with the same apparent phenotypic expression of HbS disease, have, 
with the exception of their hemolytic anemia only mild and 
inconsequential clinical sequela. (94) The co-inheritance of a gene 
for a-thalassemia or elevated levels of HbF (i.e. hereditary 
persistence of fetal hemoglobin - HPFH) have been proposed as 
factors modulating the clinical severity of sickle cell anemia. 
Thalassemia is a genetic disorder that leads to a defect in the 
production of one or more of the globin polypeptide chains of 
hemoglobin. This defect in turn leads to absent or decreased 
synthesis of the affected chain. The red blood cells of affected 
individuals tends to be hypochromic (low intracellular hemoglobin 
concentration) and microcytic (smaller than normal). 
Co-inheritance of a gene for HbS and for (3-thalassemia 
sometimes results in a milder clinical course than that experienced 
by patients with the SS phenotype. (16) The effects of a- 
thalassemia on disease severity in sickle cell anemia remains 
uncertain. It has been suggested that the effects of hypochromia on 
viscosity of blood or the diminution of internal viscosity of the red 
blood cells as a result of decreased mean HbS concentration are 
possible means by which mild symptoms of HbSS are produced. (32) 
Alpha-thalassemia is made up of four "classic" syndromes: 

1) Alpha-thalassemia-2-trait is very common in Blacks, (with a 
frequency of 15-20% in some populations). In this condition, 
all four a globin gene loci fail to operate correctly. 
2) Alpha-thalassemia-1-trait is a condition in which there are 
two dysfunctional gene loci. 
3) In HbH disease three dysfunctional a globin gene loci are 
present. 
4) In Hb Bart's, hydrops fetalis is often seen, as a result of a 
defect in all four alpha globin gene loci. 
Although the above syndromes are classically caused by 
deletion of one, two, three or all four of the a globin genes, non¬ 
deletion forms of a-thalassemia also occur. (10) 
The effect of a-thalassemia on disease severity of sickle cell 
anemia remains unproven. One study performed by Dr. Mears and his 
colleagues provided for the analysis of the alpha gene deletions by 
restriction endonuclease mapping of DNA from Black Americans and 
Africans. It was demonstrated that subjects with sickle cell 
anemia possess chromosomes bearing a gene deletions in greater 
numbers than normals or individuals with sickle trait. They also 
concluded that a gene deletions that cause a-thalassemia allow for 
prolonged survival in individuals with sickle cell anemia. Higgs et 
al., were unable to demonstrate increased survival associated with 
co-inheritance of HbS and a-thalassemia. (40) 
However, the investigators note that it is not clear if the co¬ 
inheritance of sickle cell anemia and a-thalassemia trait leads to a 




In hereditary persistence of fetal hemoglobin (HPFH), 
morphologically normal red blood cells in individuals who are 
heterozygous for the causative mutation can have HbF levels as high 
as 20-30%. Individuals who are homozygous for HPFH can produce up 
to 100% HbF. In 1961, Jackson et al. evaluated sixty-one patients 
with sickle cell anemia for clinical severity. Using a pathologic 
index rating, they found that 38 patients whose erythrocytes 
contained 12% or more HbF had a significantly lower pathologic 
index rating compared to 23 patients whose red blood cells 
contained little HbF. They concluded that the increased amounts of 
HbF protected red blood cells from sickling and thus decreased the 
degree of severity of sickle cell anemia. (46) 

V. HEMOGLOBIN SWITCHING 
The mechanism by which red blood cells switch from synthesis 
of HbF to HbA during the neonatal period had been the subject of 
much study and interest. By clarifying the means by which 
hemoglobin switching occurs, we may be able to elucidate the 
developmental regulation of gene expression as well as determine 
means of reactivating or preventing suppression of gamma globin 
gene expression. As elevated HbF levels have been linked to milder 
clinical courses in sickle cell disease and thalassemia, a potential 
form of gene or pharmacological therapy may be developed based on 
an understanding of hemoglobin switching. 
During the last six months of gestation, fetal red blood cells 
contain mostly HbF. As the first year of life progresses, the infant's 
red blood cells contain predominantly HbA. Adult red blood cells 
contain mostly HbA with small amounts of HbF and HbA2- (92) 
Figure 2 is a schematic representation of the human globin 
gene clusters and an indication of when particular hemoglobin types 
are produced in the course of human development. HbF is composed 
of two gamma chains and two alpha chains. There exists two y 
globin genes, Gy and Ay. The Gy gene encodes for glycine at position 
136 and the Ay gene encodes for an alanine residue at this position. 
During fetal development, the Gy to Ay ratio is 3:1 in RBCs. As the 
hemoglobin switch occurs in the perinatal period leading to 
increased synthesis of HbF the Gy to Ay ratio changes from 2:3 (the 
ratio seen in adult RBCs) (92) 
The exact mechanism that regulates the normal switch from y 
to (3 globin gene expression remains unknown. However, it appears 

that the switch is controlled more by a developmental clock and 
gestational age than by intrauterine or environmental factors, as 
prematurity has little effect on the process. (16) Some modulation 
of the process can occur as in intrauterine growth retardation 
(IUGR), maternal anoxia, and hyperinsulinism secondary to maternal 
diabetes mellitus in which there seems to be some delay in the 
switch. Also, in some cases of Down's syndrome (Trisomy 21) and 
the C/D chromosomal translocation syndrome, there appears to be an 
acceleration of the hemoglobin switch. (16) 
Several hypotheses exist for the mechanism of the fetal 
switch: 
-Clonal model: hemoglobin switch occurs due to a progressive 
replacement of cells derived from a fetal stem cell lineage by 
cells derived from an adult stem cell lineage. 
-Adult vs. fetal erythroid cell expression is regulated by 
changes in the degree of DNA hypomethylation and DNAase I 
hypersensitivity of the 5' flanking region of DNA of both the 
gamma and beta globin genes. 
-Regulatory DNA sequences on the inter- y/5 gene region may 
be responsible for the fetal to adult hemoglobin switch. 
(16) 
During fetal development, the y and p genes are expressed 
simultaneously. At the beginning of the liver stage of 
erythropoiesis (weeks 5-20 of gestation), the y gene is 
approximately fifty times more active than the p gene. By week 30- 
33, p chain synthesis slowly increases to approximately ten 
percent of y chain synthesis. As the rate of y chain synthesis falls, 

the synthesis of (3 chains increases dramatically. At birth, the 
normal infant has 60-80% HbF in its RBCs. By 16-20 weeks of age, 
HbF levels are approximately 3%. By age two years, HbF levels are 
usually that of adult RBCs - < 1%. (91) In adults, hemoglobin F is 
found in only a subpopulation of RBCs (usually <8%) referred to as F- 
cells. While F-cells appear to express other features of fetal red 
blood cells, they are distinct form true fetal red cells. (102) 
Various mutations have been associated with increased levels 
of HbF. In deletion mutations, there is deletion of a portion of the (3 
globin gene cluster. Non-deletion mutations reflect point mutations 
within or outside of the cluster. Both types of mutations can cause 
a uniform distribution of HbF (pancellular) or a nonuniform 
distribution (heterocellular). 
In heterocellular distribution of HbF, mutations can increase 
the percentage of F-cells and/or increase the average amount of HbF 
per F-cell. These mutations can increase Gy globin gene expression 
only, Ay globin gene expression only or both. Thalassemia mutations 
can also lead to the production of hypochromic, microcytic RBCs 
with increased HbF production. When the mutation leads to 
morphologically normal cells associated with increased HbF levels 
in heterozygous individuals, the condition is known as hereditary 
persistence of fetal hemoglobin (HPFH). (92) 
Increased production of HbF can also be observed during 
episodes of erythropoietic stress (as in recovery from 
chemotherapy, bone marrow transplantation and chronic congenital 
hemolytic anemias). For example, acute hemolysis results in 
increased F-cell production, although required or congenital chronic 
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hemolytic anemias are rarely associated with significant elevation 
in HbF levels. Also, in severe untreated iron deficiency the F-cell 
levels is within normal limits. After iron replacement there is a 
marked increase in reticulocyte response which in turn leads to 
erythroid expansion and the preferential production of F-cells. How 
accelerated erythropoiesis leads to increased F-cell production 
remains a mystery. One theory is that during erythropoietic stress 
there is an increased chance of premature commitment of early 
erythrocyte progenitors which can lead to an increase in F-cell 
production. (92) In support of this idea is the observation that in 
acutely anemic baboons F-reticulocyte levels are low. After a few 
days the F-reticulocyte levels increase. When the baboon becomes 
chronically anemic the proportion of F-reticulocytes decrease 
despite persistent reticulocytosis. This is thought to occur due to 
the expansion of the erythron which allows reticulocytosis to occur 
with less disruption of erythropoiesis and subsequently less 
probability of increased F-cell formation. (92) 
Demonstrated stimulation of HbF synthesis in vitro using bone 
marrow cultures from adults by Papayannopoulou et al. indicates 
that the HbF to HbA switch is reversible and that induction of fetal 
hemoglobin synthesis in the adult is possible. By using antibodies 
and immunofluorescent labeling these investigators were able to 
gather evidence for a cellular restriction of HbF. In a given HbF 
colony, all the cells reacted to fluorescent antibody with the same 
degree of intensity regardless of colony size. It thus seems 
probable that all the cells were programmed to have similar levels 
of y chain formation. This suggests that the signal for turning on y 

chain synthesis is present on the original stem cells from which 
colonies are derived. (68) 
The premise that y gene expression is dependent on erythroid 
stem cell differentiation and is characteristic of early erythroid 
cells was further supported by a study by TH. Papayannopoulou et al. 
in which erythroid colonies derived from primitive erythroid 
precursors demonstrated consistent activation of HbF synthesis. It 
appears that this property is lost when erythroid precursors of the 
adult further differentiate in vivo. These findings suggest that the 
use of erythroid progenitor cells may provide a useful, early 




VI. SICKLE CELL DISEASE IN SAUDI ARABIA 
Dr. H. Lehman and associates were the first to describe the 
high prevalence of the sickle cell gene in Saudi Arabia. Their 
analysis of more than 1000 blood samples from employees of the 
Arab-American Oil Company (ARAMCO) in Danman revealed that 10- 
25% of the people residing in the eastern province of Saudi Arabia 
had sickle cell trait. (53) 
Sickle cell disease in the eastern province of Saudi Arabia is 
characterized by a relatively mild clinical course which appears to 
be due to the elevated HbF levels seen in this population. It has been 
suggested that this group of patients with mild sickle cell disease 
may serve as a model for understanding what clinical sequela may be 
ameliorated via manipulation of HbF production after birth. 
In 1979, Perrine et al. described the presence of mean HbF 
levels of 22-26% in Saudi Arabian children and adults. They also 
demonstrated the presence of higher levels of HbF during the first 
few years of life in these patients. They found a mean level of HbF 
of 32%, even after the age of three. In contrast, in most other 
sickle cell populations, HbF levels fall more slowly after birth than 
normally but tends to be less than 15% by age one and less than 9% 
by age three. Forty-two patients with sickle cell disease were 
studied along with matched controls, for clinical complications 
specific for sickle cell disease. They found that vaso-occlusive 
crises were rare and generally slight in nature. Two patients 
suffered from hand-foot syndrome. Hypoplastic crises in one patient 
were severe enough to warrant blood transfusions. There was no 
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were severe enough to warrant blood transfusions. There was no 
case of acute splenic sequestration crisis. One patient had 
osteomyelitis and one had salmonella septicemia. Fourteen of the 
42 patients with sickle cell disease were hospitalized during the 
first three years of life compared to 6 of the controls. The most 
common causes of hospitalization in the sickle cell patients were 
respiratory infections and gastroenteritis. Clinical assessment of 
growth and development were within normal ranges and did not show 
significant differences from controls. There were two deaths 
reported. One child died apparently from septicemia at age 25 
months. Another child died at age 35 months from what probably 
was gastroenteritis. (75) 
Of interest is the apparent preservation of splenic function in 
Saudi Arabian children with sickle cell disease. The presence of 
Howell-Jolly bodies is thought to be a reliable indicator of loss of 
splenic function. Only one-sixth of Saudi infants with HbSS had 
Howell-Jolly bodies when studied at 18 months and older (mean age 
of 44 months). After age one, patients of African descent with HbSS 
were reported to have lost their splenic function in two-thirds to 
four-fifths of cases. (75) This fact may help explain the difference 
in mortality rates during the first two years of life: reported as 13% 
for Jamaicans and zero for the Saudi Arabians with sickle cell 
disease. (75) 
Saudi Arabians with HbSS are 34 times more likely to get 
pneumococcal meningitis, and 8 times more likely to get bacterial 
meningitis than the general population. However, Blacks in Miami 

with HbSS have a relative risk of 309 for all bacterial meningitis 
and 579 for pneumococcal meningitis. (74) 
When the mortality rates of 216 Saudi Arabs was compared 
with that of 207 Chicago Blacks they were found to be 0.9% in eight 
years and 9.1% in five years respectively. Sickling related 
complications occurred less often than seen in comparable groups of 
Blacks with HbSS from the U.S. or Caribbean. For example, none of 
the Saudi Arabians studied by Perrine and his associates in 1978 had 
a history of leg ulcers while 44% of the American or Jamaican 
Blacks did. Eight percent of the Blacks age 10-19 had femoral head 
necrosis compared to 4.4% of the Saudi Arabians in the same age 
group. Six percent of Blacks had a history of pneumococcal 
meningitis and 10% had a history of bacterial meningitis. In 
contrast, 1.5% of Saudi Arabs had pneumococcal meningitis and 2.6% 
had bacterial meningitis. (74) 
As in American, African and Caribbean Blacks, a wide spectrum 
of clinical severity is seen in Saudi Arabians with sickle cell 
disease. However, the overall clinical course of the disease is 
milder. Death was found to be rare in early childhood. The few 
deaths that have occurred in adolescents and adults from infectious 
causes may reflect slower pathological damage to vital organs; 
especially delayed splenic atrophy. Many patients have splenomegaly 
into adult life - a factor which may or may not be influencing 
susceptibility to infection. (74) 
M.A.F El-Hazmi et al. in their study of Saudi Arabians with Hb 
SS found that some patients with low HbF levels have mild 
symptoms, while others with high HbF have more severe clinical 
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manifestations, indicating that some other factors are involved in 
ameliorating sickle cell disease in Saudi Arabians. (32) 
Karim Kamel studied 11 patients with homozygous sickle cell 
anemia who were non-Sheeah Arabs from the south eastern coast of 
the Arabian peninsula and discovered that they had elevated HbF 
levels ranging from 8-18%, with a mean of 11.9%. However, he found 
no significant correlation between a patient's HbF level and the 
patient's clinical manifestations. He proposes that intermixing of 
the African sickle gene in this population is a possible explanation 
for the clinical diversity observed. (47) 
El-Hazmi also studied sickle cell disease in Arabia and found 
elevated levels of HbF. The HbF was unevenly distributed among red 
blood cells (heterocellular distribution). He proposed that acquired 
anemias such as iron deficiency or pernicious anemias may lead to 
low hemoglobin concentrations that produce a new steady state in 
which there are less frequent painful crises occurring. (30) Thus, 
genetic and acquired conditions may allow for the clinical diversity 
seen in sickle cell disease. 
An examination of 53 children from the Saudi-Arabian south 
western province with sickle cell disease by El-Hazmi et al. 
revealed some interesting findings. HbF distribution revealed 
marked variation from 1.0% to 25% with a mean of 10%. 
Hematological parameters did not show any statistically significant 
differences between subgroups with low HbF (less than 5%, 5-10%) 
and high (greater than 10%) HbF. This suggests that the HbF level is 
not the only factor influencing hematological parameters in patients 
with sickle cell disease from the south western province of Saudi 
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Arabia. Patients also demonstrated a high frequency of co¬ 
inheritance of alpha and beta-thalassemia, and G-6PD deficiency. It 
was found that total hemoglobin, RBC count and PCV had a higher 
mean value in sickle cell patients with alpha or beta thalassemia 
compared to those without thalassemia. Red cell indices (MCV, 
MCHC, MCH) were significantly lower in sickle-thalassemia patients 
but fetal hemoglobin levels did not show any statistical 
significance. (31) 
Clinical manifestations of sickle cell disease in the south 
western province of Saudi Arabia were found to be severe. All of 
the children were anemic. 85.4% had received blood transfusions and 
of these 43.9% had several blood transfusions. Seventy-eight 
percent demonstrated splenomegaly and 65.8% had hepatomegaly. 
One patient had undergone splenectomy. (31) 
A new finding in sickle cell disease patients in Saudi Arabia 
was the presence of hand-foot syndrome in 34.1% of the children 
studied from the south-western province. Vaso-occlusive crises 
were fairly common, occurring in 75.6% of those studied. Hemolytic 
crises were seen in 19.5% and infective crises in 9.7% of those 
studied. Interestingly, the presence of high HbF levels, alpha or beta 
thalassemia or G-6PD deficiency did not appear to ameliorate the 
clinical manifestations of sickle cell disease in the same way they 
appear to in the sickle cell population in the eastern province; 
although co-inheritance of alpha or beta thalassemia did improve 
hematological parameters. (31) 
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The presence of a clinically severe form of sickle cell disease 
in the Saudis that resembles the clinical course in Black Africans 
and Americans suggests the presence of a different sickle gene in 
these patients or the possibility that genetic and/or environmental 
factors that help produce a mild sickle cell disease in the eastern 
province are absent in the south western province of Saudi Arabia. 
(31) 
Red blood cells in patients with sickle cell disease, that have 
increased amounts of HbF tend to have increase survival rates. It 
has been suggested that the lower levels of HbF (usually 5-10%) that 
occurs in Blacks with HbSS is probably due to the differential 
survival of cells with HbF, rather than an actual increase in HbF 
synthesis. (74) 
Nonetheless, attempts to draw connections between clinical 
severity and HbF levels have led to ambiguous results because it is 
difficult to objectively define clinical severity and other genetic, 
environmental and physiological factors affecting clinical status . 
Wood et al., studied HbF synthesis in Saudi Arabian and African 
sickle cell patients in an attempt to determine if the increased 
level of HbF seen in the former group was due to the selective 
survival of cells with HbF or a true increase in y chain production. 
Experiments conducted in vitro and in vivo have shown that 
cells containing HbF have a longer survival in the circulation than 
cells without HbF. This is thought to be due to the inhibitory effect 
that HbF has on the sickling process of HbS molecules leading to a 
reduction in the number of red blood cells that become irreversibly 
sickled cells. (16) 
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Using single cell immunodiffusion, Dover et al. found no 
significant correlation between the amount of HbF/F-cell and the 
number of F-cells. Thus, the amount of HbF/F-cell may be an 
independent variable which also contributes to the overall levels of 
HbF. (28) Later studies revealed that the synthesis of y chains was 
considerably lower than the levels of HbF in African and Saudi 
Arabian cases; suggesting an increased role for the selective 
survival of F-cells in sustaining increased HbF levels. (102) 
In 1987, M.A.F. El-Hazmi and associates studied 285 males 
and 432 females from Al-Hafout, Al-Qateef and neighboring villages 
in the eastern province of Saudi Arabia. In the 55 SS homozygotes 
studied there were no cases of leg ulceration, or hand-foot 
syndrome. Abdominal pain and pain in the bones and joints appeared 
to be one common complaint. Almost 70% of the SS patients had 
received blood transfusions although actual sickle cell crises were 
noted as being "rare." Fifty-six percent had anemia, 36% had 
hepatomegaly, 45% had splenomegaly and osteomyelitis was seen in 
45% of the cases studied. The data for the individuals homozygous 
for the sickle cell gene revealed variation in the clinical and 
hematological data; some individuals exhibited chronic anemia and 
others almost normal values for Hb, RBC and PCV. Co-inheritance of 
a-thalassemia has been suggested as a possible modifier of the 
clinical sequela of sickle cell disease. The theory is that 
hypochromia may cause a decrease in viscosity of blood or in the 
internal viscosity of the red cell due to decreased mean cell Hb SS 
concentration and subsequently resulting in decreased intravascular 
sickling and mild symptoms. (32) 

Pembrey et al. measured HbF levels in 137 normal individuals, 
109 sickle trait individuals and 237 individuals homozygous for 
sickle cell disease. The HbF found had a heterocellular distribution. 
(73) 
Using the premise that the level of HbF in the peripheral blood 
is a result of the rate of HbF synthesis and differential destruction 
of F-cells and non F-cells, investigators sought to evaluate the 
roles of coexistent a-thalassemia and/or G-6PD deficiency in 
increasing HbF levels. If the high levels of HbF in Saudi Arabs with 
sickle cell disease was due largely to the concentration of F-cells in 
the peripheral blood there would exist a positive correlation 
between the rate of hemolysis and HbF level. The opposite was 
shown - an inverse correlation between HbF level and the 
reticulocyte count. Thus, the increased level of HbF was thought to 
be primarily due to increased synthesis of HbF which in turn 
decreased hemolysis by inhibiting cell sickling. Alpha-thalassemia 
and G-6PD deficiency were also shown to have little effect on 
promoting high levels of HbF (73) 
The heterocellular distribution of HbF and low levels of HbF 
found in normal (AA) individuals and individuals with sickle cell 
trait (AS) excludes the pancellular, Negro and Greek forms of HPFH 
as possible explanations for the increased levels of HbF seen in 
Saudi Arabians with sickle cell disease. Population surveys have 
revealed little difference in HbF levels in normal and sickle trait 
individuals of Arabian or African descent. Low levels of HbF in 
normal and AS individuals excludes the possibility of a co-dominant 
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heterocellular HPFH gene in linkage disequilibrium with the sickle 
gene. (73) 
Another possibility is that there is present a truly recessive 
HPFH gene which is in linkage disequilibrium with the sickle gene. 
This hypothesis would prove to be true if individuals from the Saudi 
Arabian oasis population with sickle p°-thalassemia have similar 
high levels of HbF. (72) 
Using a radioimmunoassay to assess the amount of HbF 
produced in vitro by erythroid progenitor-derived erythroblasts, 
investigators have sought to determine the basis of increased HbF. 
Results of this study revealed that HbF synthesis is a major 
contributor to increased HbF levels in Saudi Arabians with sickle 
cell anemia. The findings also suggest that the high HbF levels are 
inherited from at least one parent but its expression requires 
increased erythropoiesis. The Saudi Arabian patients studied 
consistently had an increased ratio of Gy to Ayglobin. In contrast, 
80% of Black Americans with sickle cell disease have 40% Gy and 
60% Ay with only 20% having more Gy than Ay. (59) 
Interestingly, Miller and her colleagues found that patients 
homozygous or heterozygous for the ++-++ haplotype and with the SS 
phenotype have an increased level of HbF synthesis. However, 
homozygosity for the ++-++ haplotype in and of itself did not appear 
to control HbF levels. Individuals heterozygous for the sickle gene 
and homozygous for ++-++ had only modest elevations in HbF. (58) 
Miller proposes that the amount of HbF produced depends on 
erythropoietic stress, the degree of maturation of the progenitor 
cells and the "permissiveness" of the yglobin gene. 

In a follow-up study, Miller studied 55 members of five 
families with sickle cell disease to determine if the specific yp gene 
cluster seen in these individuals could explain the increased HbF 
levels, increased Gy/Ay ratio and elevated HbF production by 
progenitor derived erythroblasts. Starting with the knowledge that 
most Saudis with sickle cell anemia were homozygous for the 
haplotype ++-++++- characterizing the p globin gene cluster, the y 
globin gene region was isolated via molecular cloning. The 
nucleotide substitution C-> T at position -158 5' to the Gy cap site 
was recognized using restriction endonucleases. The results 
revealed that Saudis homozygous or heterozygous for the sickle gene 
with a -158 C->T substitution, even on one chromosome, had an 
elevated level of Gy > 50%. No significant differences were found 
between heterozygotes or homozygotes with the C->T substitution 
on one or both chromosomes. This suggests that while an increase in 
Gy globin may be associated with the C->T substitution it does not 
necessarily produce a measurable increase in total HbF production. 
(58) 
Miller also found that Saudis with one copy of the "common" 
eastern oasis haplotype +++-S do not have elevated total circulating 
HbF (in contrast to their African and Mediterranean counterparts) 
but did demonstrate variable increases in the Gy /Ay ratio ratio. The 
authors confirmed their previous finding that the presence of the 
+++-S yp haplotype on both chromosomes correlated with the 
extent of HbF production in Saudis. This association does not 
suggest a tight linkage. The authors hypothesize that the -158 C->T 
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substitution may increase the ability of the Gy region to respond to 
transacting proteins. The actual amount of the HbF produced in red 
blood cells may be dependent upon the intracellular level of these 
transacting proteins and cm the specific DNA sequences near and/or 
far away from the yglobin genes. Also, erythropoietic stress may 
affect the transacting regulatory protein levels and lead to 
increased expression of Gy genes and total HbF. (58) The 
identification of the regulatory proteins controlling globin gene 
expression and description of their function will help to clarify 
factors responsible for the HbF levels in Saudi Arabians and others 
with sickle cell anemia. 

VII. SICKLE CELL DISEASE IN KUWAIT 
3 3 
The high frequency of the sickle gene in the region bordering 
the western coast of the Arabian gulf appears to be due to three 
factors: 
1) Falciparum malaria was endemic in this area into the 
mid-20th century, allowing for a selective survival 
advantage to heterozygotes. 
2) Homozygous disease appears to be compatible with 
survival into adult life and reproduction. 
3) A high rate of consanguinity exists with frequent first 
cousin marriages). (71) 
Of the Kuwaiti patients studied by Pearson et al., 47 were 
found to have Hb SS disease while 21 had Hb Sp-thalassemia. No 
significant difference was found between the Kuwaiti Hb SS 
patients and the Hb Sp-thalassemia patients in regards to 
hemoglobin level, reticulocyte count, and percent HbF. This is 
similar to the situation seen in the U.S., where Sp-thalassemia and 
SS patients have similar clinical and hematological pictures. (71) 
Kuwaiti sickle cell patients were compared with American 
sickle cell patients and the former group was found to have higher 
levels of HbF than the latter group. Hemoglobin levels were 
significantly higher and reticulocyte counts significantly lower in 
Kuwaiti patients. (71) Hemoglobin levels in the Kuwaiti sickle cell 
disease patients ranged from 70-120 g/L. None of their American 




Kleinhauer-Betke preparations were done on six Hb SS and four 
Hb Sp-thalassemia Kuwaiti patients and all revealed a 
heterogeneous distribution of HbF in their erythrocytes; a finding 
similar to that seen in Saudi Arabians with sickle cell disease. (71) 
Analysis of clinical records of Kuwaiti patients by Pearson et 
al., revealed a relatively mild clinical course for most. Only 10% had 
experienced sickle cell dactylitis (hand-foot syndrome) compared to 
one-third of the American cases. Painful crises appeared to be 
more responsive to analgesia and IV hydration than American cases. 
There were no new episodes of splenic sequestration syndrome and 
only one episode of stroke and two episodes of Salmonella 
osteomyelitis at the Sabah Children's Hospital between 1976-1985. 
(71) 
Eighteen of 21 patients with Sp-thalassemia and 13 out of 47 
with SS disease had splenomegaly. No American sickle cell patients 
had palpable splenomegaly. Thirty-five percent of Kuwaiti patients 
with Sp-thalassemia had weights < 10th percentile and 75% of 
Kuwaiti HbSS patients had weights at this level. In the American 
group, 35% showed this degree of growth delay. (71) 
During the years 1976-1983, only one Kuwaiti sickle cell 
patient died. This death was determined to be due to causes 
unrelated to sickle cell disease. There were no recognized causes of 
overwhelming sepsis, which is seen in 10-20% of patients in the U.S. 
The lack of severe infectious complications in Kuwaiti sickle cell 
patients may be due to the overall preservation of splenic function. 
(71) 

Pearson et al., evaluated this premise by analyzing the amount 
of pocked RBCs found in Kuwaiti versus American sickle cell disease 
patients. Preservation of splenic function associated with a low 
percentage of pocked RBCs in sickle cell patients from the eastern 
province of Saudi Arabia has been reported. Pearson et al., found 
that in 10 Kuwaiti patients with HbF levels > 15% and concomitant 
Hb SS or Hb Sp-thalassemia, all had normal splenic function. Of 
note, all the American cases had >10% pocked RBCs indicating 
functional hyposplenism. (71) 
A third of patients with a hemoglobin SF electrophoretic 
pattern (21/68) were shown by family studies to have the Sf% 
thalassemia genotype. It appears that the a-thalassemia gene may 
also be prevalent in Kuwait as some of the individuals with 
homozygous sickle cell disease had microcytosis. (71) 
American sickle cell patients have a greater degree of 
hemolysis than their Kuwaiti counterparts as demonstrated by their 
lower mean hemoglobin levels and higher reticulocyte counts. Vaso- 
occlusive events are less frequent and less severe in Kuwaiti 
patients, which may be due to the higher levels of HbF seen in this 
group. Most of the Kuwaiti patients with Hb SS and Hb Sb- 
thalassemia have HbF levels between 10-20% into adolescence. In 
contrast, American cases of Hb SS and Sp-thalassemia rarely 
display HbF levels > 10% after ten years of age. (71) 
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However, sickle cell disease in Kuwait is not "benign." Several 
Kuwaiti patients with low levels of HbF (2-6%), had frequent painful 
crises, requiring hospitalization and frequent blood transfusions. 
Also, longitudinal studies on a larger population of sickle cell 
patients in Kuwait may reveal complications which may only be 
apparent in older patients. (71) 

VIII. MECHANISMS MODULATING FETAL HEMOGLOBIN LEVELS 
Studies lend support to the hypothesis that at least three 
variables contribute to high HbF levels: 
(1) The percentage of RBCs and reticulocytes containing HBF. 
(2) The quantity of HbF synthesized within F-cells. 
(3) The extent to which preferential F-cell survival increases HbF 
levels. (28) 
Dover et al., concluded that these variables are independently 
regulated and that the expression of each variable is distinctly 
different between individual patients. They also determined that 
the production of HbF may be as great in the absence of 
heterocellular HPFH as in its presence. While the investigators 
agreed that HbF offered RBCs protection against premature loss, the 
degree to which it does so was felt to be variable from one 
individual to another. The inherent implication of this is that there 
exists a factor (or factors) other than HbF levels that modifies F- 
cell production and survival. (28) 
An analysis of in vivo changes in F-cell production supports 
the hypothesis that increased F-cell production is associated with 
accelerated erythropoiesis. F-cell production in a child with sickle 
cell anemia was found to be reduced to a greater degree than non-F- 
cell production when erythropoiesis is suppressed. This lends 
support to the idea that F-cell production is regulated separately 
from non-F-cell production. It is not clear if falling erythropoietin 
levels and subsequent depressed erythropoiesis are associated with 
selective depression of F-cell production. (29) The authors 
conclude that individuals with sickle cell anemia like individuals 
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with normal hemoglobin, can change their relative F-cell production 
in response to erythropoietic stress via a process that is under a 
different system of regulation than non-F-cells. (29) 
By examining y globin gene expression, haplotypes associated 
with elevated FlbF levels and the clinical course of sickle cell 
patients with high FlbF, it is hoped that the mechanisms regulating 
HbF synthesis will be clarified. In the Saudi Arabian population, a 
milder form of sickle cell disease is found that is associated with 
high HbF levels. A similar syndrome can also be seen in Asian- 
Indians with sickle cell disease. Interestingly, unlike Jamaican or 
American Blacks with sickle cell disease and high hemoglobin F 
levels, one usually cannot identify in Saudi or Indian families a 
parent with slight elevation of HbF - a finding that would be 
consistent with the Swiss type of heterocellular HPFH. (16) 
In Swiss type HPFH, an autosomal dominant inheritance 
pattern leads to slightly elevated HbF levels usually in the range of 
2-3% in heterozygotes. The HbF produced has both Gy and Ay 
subtypes of the y globin chains. Individuals with Swiss type HPFH 
and a hemoglobinopathy are often asymptomatic. The molecular 
defect in Swiss type HPFH is unknown. (16) 
F-cell production in sickle cell anemia may be regulated by a 
genetic locus that is linked to or separate from the (3 globin gene 
cluster. Attempts to elucidate mechanisms modifying F-cell 
production are compounded by the preferential survival of F-cells 
that varies from individual to individual and thus serves as a poor 
indicator of actual levels of F-cell production. (24) Dover et al. 
correlated F-reticulocyte levels in sibling pairs with SS disease and 

between parents and their children and found that genes controlling 
F-cell levels are linked to the p globin gene site and that these 
genes also control F-cell production in non-anemic individuals. (24) 
Boyer et al., in a later study, again looked at F-cell production 
in an attempt to determine if it is regulated by a site (or sites) 
separate from the p globin gene cluster. Results revealed a 
substantial number of sibling pairs with discordant F-reticulocyte 
levels. The discordance was found to be significant and 
reproducible. Polymorphic markers were used to ascertain that the 
discordance appeared in siblings who almost certainly had the same 
mother and father. (12) Boyer et al., concluded that at least one 
genetic regulator of F-cell production in sickle cell anemia 
segregated separately from sickle hemoglobin. A gene separate from 
the p globin gene cluster may regulate F-cell production by 
elaborating or modifying a substance that interacts with a receptor 
or effector site on the p globin gene region. Mutations in the 
modifying substance or gene site itself could then control levels of 
F-cell production. 
Another hypothesis, supported by the finding that HbF 
synthesis in vivo is usually completed early in erythroid maturation, 
is that a gene (or genes) can control HbF levels by influencing the 
percentage of cells in various stages of development when the F-cell 
"window" is open. (12) 
The finding that 5-azacytidine increases F-reticulocytes from 
10% to as much as 52% in sickle cell anemia patients has caused 
cautious optimism that new therapeutic modalities for sickle cell 
disease may be on the horizon. The rise in F-reticulocyte levels 
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from the use of 5-azacytidine has been associated with a 
demethylation v of DNA associated with y globin genes from bone 
marrow erythroid cells. The persistence of fetal hemoglobin in 
childhood and adulthood may be due to mutations in the y globin gene 
associated DNA which inhibit methylation later in life. (62) 

IX. EXPERIMENTAL OBJECTIVES 
The purpose of our study was to examine the levels of HbF in 
patients with sickle cell disease in the Kuwaiti population. 
Furthermore, an analysis of 7 globin gene expression in these 
patients was undertaken in an attempt to facilitate scientific 
understanding of the mechanisms involved in increasing 7 chain 
synthesis. 
X. METHODS AND MATERIALS 
Solutions & Buffers 
Solution A: 10% Ammonium Persulfate (fresh) 
Solution B: 60% Acrylamide + 0.4% Bis (stored at 4° C; redissolved 
in a 37°C water bath) 
Solution C: 10% Triton X-100 
Solution D: (Loading Buffer): 6M Urea + 8% HAC + 8% (3- 
mercaptoethanol + 0.3 mg/ml pyronine Y 
1 M Cysteamine 
Lysis Buffer: 5mM MgCl2 (stored at 4°C) 
Coomassie Blue Stain Solution: .62 g Coomassie Blue in 10% acetic 
acid and 45% methanol solution 
Destain Solution: 10% acetic acid and 10% methanol solution 
Acid Acetone: 2 ml 12N HCI + 38 ml acetone + 3001 b- 
mercaptoethanol 
Hemoglobin Purification 
Blood samples from seven pedigree families and eight 
individuals with various forms of sickle cell and/or thalassemia 
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syndrome (including SF, Sickle (3-thalassemia, (3-thalassemia 
intermedia) were collected via venipuncture at Al-Sabah Children's 
Hospital in Kuwait. HbF levels were determined by alkali 
denaturation. 
Erythrocytes from peripheral blood of patients was washed 
three times in an equal volume of phosphate buffered saline (PBS). 
Between each washing the sample was centrifuged at 2000 rpm for 
five minutes in a RC-2 Sorvall refrigerated centrifuge. The serum 
layer was carefully removed with a Pasteur pipette. The sample 
was then solubilized at 4° C for 10 minutes in four volumes of lysis 
buffer. The sample was then centrifuged at 10,000 rpm (using a HB- 
4 rotor) for 20 minutes. The liquid layer containing hemoglobin was 
removed with a Pasteur pipette (without disturbing the layer of 
cellular debris at the bottom of the tube), placed in labelled tubes 
and stored at -70° C. 
Some of our blood samples had lysed prematurely during 
transit from Kuwait. From these samples globin preps were made 
using acid acetone. Acid acetone at 4° C was added in a 1:20 volume 
to our sample. The mixture was centrifuged in a RC-2 Sorvall 
centrifuge for five minutes at 10,000 rpm. The liquid supernatent 
layer was discarded and the pellet was washed three times with 
plain acetone at 4° C. The pellet was then dried using nitrogen gas. 
The pellet was resuspended in 500 microliters of loading buffer 
(Solution D), placed in an appropriately labelled tube and stored at - 
70° C. 

Triton Gel Electrophoresis 
A 12.5% polyacryalmide gel with 6M urea, 2% Triton X-100 in 
5% acetic acid was used to separate the globin chains, using a 
procedure previously described by Rovera et al. (84) 
The gel was prepared by combining 2 ml of solution B + 0.5 ml 
glacial acetic acid + 25CRTEMED (N.N.N'.N', - tetramethylenediamine) 
+ 18 grams urea and distilled water to bring the volume up to 49 ml. 
The solution was vortexed and degassed under a vacuum. Three 
hundred microliters of solution A and 1 ml of 100% Triton were 
added to the gel solution. The gel was then poured between two 
glass plates with spacers. It was overlaid with distilled water and 
allowed to polymerize. After polymerization occurred the top 
spacer was removed and the gel was overlaid with distilled water. 
The gel was pre-electrophoresed for one hour at 200 V with 5% 
acetic acid running buffer. The buffer was then removed and the gel 
was overlaid with 1M cysteamine (10 microliters per well). The 
reservoir was refilled with 5% acetic acid running buffer and 
electrophoresed for 45 minutes at 140 V. Buffer was again removed 
and hemoglobin samples applied (2-5 microliters lysate in 30 
microliters of solution D). Normal adult and fetal hemoglobin 
samples were run as controls. The gel was electrophoresed at 60 
volts for 8-16 hours with the current running backwards towards 
the anode. Gels were stained for 30 minutes with Coomassie Blue 
and destained by diffusion in 10% acetic acid and 10% methanol. The 




Familv # Identification 
Unrelated R.W. (patient) 
individuals S.A. (patient) 
with high S.D. (patient) 
HbF A.S. (patient) 
M.A. (patient) 
H.H. (patient) 
Family #1 Faiza (patient) 
Father 
Family #2 M. B. (patient) 
N. J. (mother) 
B.O. (father) 
Family #3 A.S. (patient) 
S.A. (father) 
G.B. (mother) 














Diaanosis %HbF Gy/ Ay 
SF 16% 1:1 
Sickle-p0 thal 15.5% 1:1 
Sickle-p0 thal 21.7% 1:1 
p-thal intermedia 37.5% 1:1 
Sickle-p thal 10.4% 1:1 
SF 16% 1:1 
homozygous 60.7% 1:1 
Sp-thal 
Sickle-p0 thal 9.7% 1:1 
SF 33% 1:1 
AS <2% 1:1 
AS <2% 1:1 
SF 22% 1:1 
AS <2% 1:1 
AS <2% 1:1 
ASF 15% 1:1 
SF ★ 1:1 
AS <2% 1:1 
AS <2% 1:1 
ASF 24% 1:1 
SF 24% 1:1 
SF ★ 1:1 
AS <2% 1:1 
AS <2% 1:1 
SF 32% 1:1 
AS 20% 1:1 
AS <2% 1:1 
AS <2% 1:1 
A? <2% 1:1 
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Family #7 L.S. (patient) SF 23% 1:1 
S.J. (father) AS <2% 1:1 
S.M. (mother) AS <2% 1:1 
*— Denotes inability to accurately quantify %HbF 
ASF - Electrophoresis revealed hemoglobins F, A and S 
Our data revealed: 
(1) All of the Kuwaiti sickle cell disease patients sampled, 
exhibited high levels of HbF, ranging from 10.4-60.7% 
(2) The expression of each of the gamma globin genes, Gy and Ay, 
is equal in the Kuwaiti patients studied. 
(3) Our results were similar to those seen in the analysis of the 
Gy/Ay ratio in Saudi Arabians with mild sickle cell disease 
due to heterocellular HPFFI. However, Kuwaitis do not exhibit 
classical HPFH, as the parents of affected individuals do not 







Sickle B° Thalassemia 
B Thalassemia Intermedia 
Sickle B Thalassemia 
Sickle B° Thalassemia 
Homozygous S-B°Thalassemia 
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mouse model for for sickle cell disease. In a series of experiments, 
the dominant control region (DCR) sequences which flank the (3 globin 
gene locus, were used to direct the copy number dependent 
expression of human p globin gene in erythroid cells and transgenic 
mice. By linking the p globin DCR sequences to the human alpha 
globin gene, high level expression can be obtained. One of the 
transgenic mice revealed no abnormal somatic development, and no 
obvious evidehce of hemolytic anemia, although HbS concentration 
was 83%. It is possible that the 17% normal mouse hemoglobin 
offered some protection against hemolytic anemia, just as similar 
amounts of fetal hemoglobin appear to protect human ps/HPFH 
heterozygotes. Greaves et al. note however that one cannot 
disregard the physico-chemical properties and microcirculatory 
changes that may be responsible for this clinical picture. The future 
development of an animal model for sickle cell disease could serve 
to further define the factors mediating clinical severity in sickle 
cell disease as well as screen potential anti-sickling agents. This 
animal model could also serve as a template for the development of 
somatic gene therapy using the p globin DCR. (38) 
New therapeutic options for the treatment of sickle cell 
disease may also be developed and the technology of molecular 
genetics improves. With the advent of recombinant DNA technology, 
molecular cloning of the human globin gene is now possible. 
Nucleotide sequences have been modified (by acetylation or 
methylation of "key" nitrogenous bases) to deliniate elements 
involved in the regulation of globin gene expression. Use of 
restriction enzymes has led to the mapping of the various sickle cell 
:"!0i*0! i. - •- 
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alleles and further understanding of the interaction between sickle 
hemoglobin states and alpha thalassemia. (10) 
The molecular basis for the predominance of y globin gene 
expression during gestation and the subsequent switch to (3 gene 
expression just prior to birth remains incompletely understood. 
However, many agree that prevention or reversal of this switch 
would help to decrease the clinical severity for patients with sickle 
cell anemia. Such an intervention would decrease or suppress 
expression of abnormal (3 genes and replace their gene products with 
HbF, the product of y globin gene expression. 
Therapeutic manipulation of y and (3 globin gene expression may 
be obtainable via further clarification of the effect of methyl, 
acetyl or other moieties on particular nitrogenous bases. 
Hypomethylation has been associated with high levels of gene 
activity. Disimone et al. in a series of experiments showed that 
treatment of baboons with the methylation inhibitor 5-azacytidine 
(a cancer chemotherapy drug) led to high levels of fetal hemoglobin 
production. The toxicity of 5-azacytidine and unknown effects of 
the drug on other genes make it unsuitable for widespread clinical 
use. 
The polymerase chain reaction (PCR), designed to 
enzymatically amplify selective sequences of DNA, allows for sickle 
cell disease to be identified quickly and easily. PCR and subsequent 
direct DNA sequencing may allow for identification of deletions, or 
mutations associated with high HbF levels. While restriction 
enzyme mapping is a quick and easy technique, it is limited to the 
linkage analysis of polymorphic restriction sites and to situations 
:£} 
in which the mutation creates or disrupts a restriction site. PCR 
and subsequent DNA sequencing or analysis with allele specific 
oligonucleotide probes can serve as a more general means of 
investigating possible causes of the clinical heterogeneity seen in 
sickle cell disease. (85) 
In summary, we analyzed hemoglobin F levels and expression of 
the y globin genes in a population of Kuwaiti patients with mild 
sickle cell disease. While the Gy/Ay ratio of 1:1 was lower than the 
fetal ratio of 7:3, it remains higher the the 2:3 ration seen in normal 
adult RBCs. Previous studies have defined an association between 
high HbF levels and decreased morbidity and mortality in sickle cell 
patients. We propose that future studies should provide for the 
cloning and sequencing of the y and p globin gene region and their 
promoters as well as in-depth linkage analysis to delineate 
molecular mechanisms that may serve to increase PlbF levels under 
conditions of severe erythropoietic stress. Molecular determinants 
of HbF production and/or clinical heterogeneity may be closely 
linked to the p globin gene cluster, linked to the p globin gene 
cluster but outside of the region spanning the e to cppl- globin genes 
or farther away on chromosome lip or even on a different 
chromosome. (61) It is likely that such linkage analysis will serve 
to clarify and accurately define on a molecular basis, a number of 
"sickle cell syndromes" that currently fall under the general rubric 
of sickle cell disease. 

MAJOR SICKLE p GLOBIN GENE HAPLOTYPES 




H Hd Hd H H A Hp B 
Figure 1 
The haplotype is characterized by the presence or absence (+ or -) of an 
array of of polymorphic restriction sites within the p globin gene 
cluster. (5 1) 
H = Hindi I 
Hd = Hindi 11 
A = Aval I 
Hp = Hpal 
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